메뉴 건너뛰기




Volumn 47, Issue 7, 2008, Pages 627-638

The pediatrician's role in preventing cervical cancer

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; CAPSID PROTEIN; HEPATITIS A VACCINE; L1 PROTEIN; PHOSPHORYL LIPID A; PLACEBO; WART VIRUS VACCINE;

EID: 48449087494     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922808315219     Document Type: Note
Times cited : (1)

References (64)
  • 5
    • 84876241065 scopus 로고    scopus 로고
    • Human papillomavirus
    • Atkinson WHJ, McIntyre L, Wolfe S, eds. 10th ed. Washington DC: Public Health Foundation;
    • Centers for Disease Control. Human papillomavirus. In: Atkinson WHJ, McIntyre L, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10 th ed. Washington DC: Public Health Foundation ; 2007.
    • (2007) Epidemiology and Prevention of Vaccine-Preventable Diseases
    • For Disease Control, C.1
  • 6
    • 0032840918 scopus 로고    scopus 로고
    • Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
    • Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 ; 189: 12-19.
    • (1999) J Pathol , vol.189 , pp. 12-19
    • Walboomers, J.M.1    Jacobs, M.V.2    Manos, M.M.3
  • 8
    • 0033054137 scopus 로고    scopus 로고
    • Utilization of physician offices by adolescents in the United States
    • Ziv A., Boulet JR, Slap GB Utilization of physician offices by adolescents in the United States. Pediatrics. 1999 ; 104: 35-42.
    • (1999) Pediatrics , vol.104 , pp. 35-42
    • Ziv, A.1    Boulet, J.R.2    Slap, G.B.3
  • 9
    • 3142661757 scopus 로고    scopus 로고
    • Against which human papillomavirus types shall we vaccinate and screen? the international perspective
    • Munoz NB, Castellsague FX, de Sanjose M., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 ; 111: 278-285.
    • (2004) Int J Cancer , vol.111 , pp. 278-285
    • Munoz, N.B.1    Castellsague, F.X.2    De Sanjose, M.3
  • 10
    • 31544483659 scopus 로고    scopus 로고
    • Bethesda, MD: National Cancer Institute
    • Ries L., Melbert D., Krapcho M., et al (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute, http:seer.cancer. gov/csr.1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site 2007.
    • (2006) SEER Cancer Statistics Review, 1975-2004
    • Ries, L.1    Melbert, D.2    Krapcho, M.3
  • 11
    • 0037434411 scopus 로고    scopus 로고
    • Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis
    • Clifford GM, Smith JS, Plummer M., Munoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003 ; 88: 63-73.
    • (2003) Br J Cancer , vol.88 , pp. 63-73
    • Clifford, G.M.1    Smith, J.S.2    Plummer, M.3    Munoz, N.4    Franceschi, S.5
  • 12
    • 0033516292 scopus 로고    scopus 로고
    • Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions
    • Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999 ; 91: 954-960.
    • (1999) J Natl Cancer Inst , vol.91 , pp. 954-960
    • Liaw, K.L.1    Glass, A.G.2    Manos, M.M.3
  • 13
    • 0035956499 scopus 로고    scopus 로고
    • Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia
    • Schlecht NF, Kulaga S., Robitaille J., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001 ; 286: 3106-3114. 14. Moscicki AB, Schiffman M., Kjaer S., Villa LL Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006 ; 24 (suppl 3). 42S - 51S.
    • (2001) JAMA , vol.286 , Issue.3 , pp. 3106-3114
    • Schlecht, N.F.1    Kulaga, S.2    Robitaille, J.3    Ab, M.4    Schiffman, M.5    Kjaer, S.6    Villa, L.L.7
  • 14
    • 33750375064 scopus 로고    scopus 로고
    • Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer
    • Wheeler CM, Hunt WC, Schiffman M., Castle PE Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006 ; 194: 1291-1299.
    • (2006) J Infect Dis , vol.194 , pp. 1291-1299
    • Wheeler, C.M.1    Hunt, W.C.2    Schiffman, M.3    Castle, P.E.4
  • 15
    • 11844287672 scopus 로고    scopus 로고
    • A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women
    • Brown DR, Shew ML, Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005 ; 191: 182-192.
    • (2005) J Infect Dis , vol.191 , pp. 182-192
    • Brown, D.R.1    Shew, M.L.2    Qadadri, B.3
  • 16
    • 0035919183 scopus 로고    scopus 로고
    • Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females
    • Moscicki AB, Hills N., Shiboski S., et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001 ; 285: 2995-3002.
    • (2001) JAMA , vol.285 , pp. 2995-3002
    • Ab, M.1    Hills, N.2    Shiboski, S.3
  • 17
    • 15944369977 scopus 로고    scopus 로고
    • Atypical squamous cells of undetermined significance: Human papillomavirus testing in adolescents
    • Boardman LA, Stanko C., Weitzen S., Sung CJ Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol. 2005 ; 105: 741-746.
    • (2005) Obstet Gynecol , vol.105 , pp. 741-746
    • Boardman, L.A.1    Stanko, C.2    Weitzen, S.3    Sung, C.J.4
  • 19
    • 33847407936 scopus 로고    scopus 로고
    • Prevalence of HPV infection among females in the United States
    • Dunne EF, Unger ER, Sternberg M., et al. Prevalence of HPV infection among females in the United States. JAMA. 2007 ; 297: 813-819.
    • (2007) JAMA , vol.297 , pp. 813-819
    • Dunne, E.F.1    Unger, E.R.2    Sternberg, M.3
  • 20
    • 0032510076 scopus 로고    scopus 로고
    • Natural history of cervicovaginal papillomavirus infection in young women
    • Ho GY, Bierman R., Beardsley L., Chang CJ, Burk RD Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998 ; 338: 423-428.
    • (1998) N Engl J Med , vol.338 , pp. 423-428
    • Ho, G.Y.1    Bierman, R.2    Beardsley, L.3    Chang, C.J.4    Burk, R.D.5
  • 21
    • 0034085544 scopus 로고    scopus 로고
    • Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection
    • Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000 ; 181: 1911-1919.
    • (2000) J Infect Dis , vol.181 , pp. 1911-1919
    • Carter, J.J.1    Koutsky, L.A.2    Hughes, J.P.3
  • 22
    • 21244491065 scopus 로고    scopus 로고
    • Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: Biologic progression or independent lesions
    • Agorastos TM, Lambropoulos D., Chrisafi AF, et al. Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions ? Eur J Obstet Gynecol Reprod Biol. 2005 ; 121: 99-103.
    • (2005) Eur J Obstet Gynecol Reprod Biol , vol.121 , pp. 99-103
    • Agorastos, T.M.1    Lambropoulos, D.2    Chrisafi, A.F.3
  • 23
    • 0032169416 scopus 로고    scopus 로고
    • Coexistence of low and high grade squamous intraepithelial lesions of the cervix: Morphologic progression or multiple papillomaviruses
    • Park J., Sun D., Genest DR, et al. Coexistence of low and high grade squamous intraepithelial lesions of the cervix: morphologic progression or multiple papillomaviruses ? Gynecol Oncol. 1998 ; 70: 386-391.
    • (1998) Gynecol Oncol , vol.70 , pp. 386-391
    • Park, J.1    Sun, D.2    Genest, D.R.3
  • 24
    • 0027468148 scopus 로고
    • Natural history of cervical intraepithelial neoplasia: A critical review
    • Ostor AG Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993 ; 12: 186-192.
    • (1993) Int J Gynecol Pathol , vol.12 , pp. 186-192
    • Ostor, A.G.1
  • 25
    • 0042345044 scopus 로고    scopus 로고
    • Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis
    • Clifford GM, Smith JS, Aguado T., Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003 ; 89: 101-105.
    • (2003) Br J Cancer , vol.89 , pp. 101-105
    • Clifford, G.M.1    Smith, J.S.2    Aguado, T.3    Franceschi, S.4
  • 26
    • 48449091698 scopus 로고    scopus 로고
    • National Cancer Institute. Cervical cancer: screening. http://www.cancer.gov/cancertopics/pdq/screening/cervical/healthprofessional. Updated July 21, 2006. Accessed January 17, 2007.
    • (2006) Cervical Cancer: Screening
    • Cancer Institute, N.1
  • 27
    • 0034673956 scopus 로고    scopus 로고
    • Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review
    • Nanda K., McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000 ; 132: 810-819.
    • (2000) Ann Intern Med , vol.132 , pp. 810-819
    • Nanda, K.1    McCrory, D.C.2    Myers, E.R.3
  • 28
    • 33748098682 scopus 로고    scopus 로고
    • Cervical cancer screening, abnormal cytology management, and counseling practices in the United States
    • Irwin K., Montano D., Kasprzyk D., et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006 ; 108: 397-409.
    • (2006) Obstet Gynecol , vol.108 , pp. 397-409
    • Irwin, K.1    Montano, D.2    Kasprzyk, D.3
  • 29
    • 34447515192 scopus 로고    scopus 로고
    • Accuracy of liquid based versus conventional cytology: Overall results of new technologies for cervical cancer screening randomised controlled trial
    • Ronco G., Cuzick J., Pierotti P., et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomised controlled trial. BMJ. 2007 ; 335 (7609). 28.
    • (2007) BMJ , vol.335 , Issue.7609 , pp. 28
    • Ronco, G.1    Cuzick, J.2    Pierotti, P.3
  • 30
    • 0142009535 scopus 로고    scopus 로고
    • How often should we screen for cervical cancer
    • Feldman S. How often should we screen for cervical cancer ? N Engl J Med. 2003 ; 349: 1495-1496.
    • (2003) N Engl J Med , vol.349 , pp. 1495-1496
    • Feldman, S.1
  • 34
    • 1342287618 scopus 로고    scopus 로고
    • The estimated direct medical cost of sexually transmitted diseases among American youth, 2000
    • Chesson HW, Blandford JM, Gift TL, Tao G., Irwin KL The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004 ; 36: 11-19.
    • (2004) Perspect Sex Reprod Health , vol.36 , pp. 11-19
    • Chesson, H.W.1    Blandford, J.M.2    Gift, T.L.3    Tao, G.4    Irwin, K.L.5
  • 35
    • 33947595236 scopus 로고    scopus 로고
    • Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    • Markowitz LE, Dunne EF, Saraiya M., et al. Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007 ; 56: 1-24.
    • (2007) MMWR , vol.56 , pp. 1-24
    • Le, M.1    Dunne, E.F.2    Saraiya, M.3
  • 37
    • 0038806720 scopus 로고    scopus 로고
    • The health and economic burden of genital warts in a set of private health plans in the United States
    • Insinga RP, Dasbach EJ, Myers ER The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003 ; 36: 1397-1403.
    • (2003) Clin Infect Dis , vol.36 , pp. 1397-1403
    • Insinga, R.P.1    Dasbach, E.J.2    Myers, E.R.3
  • 38
    • 27344444702 scopus 로고    scopus 로고
    • The role of illness perceptions: Psychological distress and treatment-seeking delay in patients with genital warts
    • Ireland JA, Reid M., Powell R., Petrie KJ The role of illness perceptions: psychological distress and treatment-seeking delay in patients with genital warts. Int J STD AIDS. 2005 ; 16: 667-670.
    • (2005) Int J STD AIDS , vol.16 , pp. 667-670
    • Ireland, J.A.1    Reid, M.2    Powell, R.3    Petrie, K.J.4
  • 39
    • 2342613014 scopus 로고    scopus 로고
    • Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
    • Goldie SJ, Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004 ; 96: 604-615.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 604-615
    • Goldie, S.J.1    Kohli, M.2    Grima, D.3
  • 42
    • 0028845930 scopus 로고
    • Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation
    • Jansen KU, Rosolowsky M., Schultz LD, et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 1995 ; 13: 1509-1514.
    • (1995) Vaccine , vol.13 , pp. 1509-1514
    • Jansen, K.U.1    Rosolowsky, M.2    Schultz, L.D.3
  • 43
    • 0030001427 scopus 로고    scopus 로고
    • Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
    • Kirnbauer R., Chandrachud LM, O' Neil BW, et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996 ; 219: 37-44.
    • (1996) Virology , vol.219 , pp. 37-44
    • Kirnbauer, R.1    Chandrachud, L.M.2    Neil, B.W.3
  • 44
    • 0029610072 scopus 로고
    • Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
    • Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995 ; 92: 11553-11557.
    • (1995) Proc Natl Acad Sci U S a , vol.92 , pp. 11553-11557
    • Suzich, J.A.1    Ghim, S.J.2    Palmer-Hill, F.J.3
  • 45
    • 0034465117 scopus 로고    scopus 로고
    • Improving vaccine performance with adjuvants
    • Vogel FR Improving vaccine performance with adjuvants. Clin Infect Dis. 2000 ; 30 (suppl 3). 266S - 270S.
    • (2000) Clin Infect Dis. , vol.30 , Issue.3
    • Vogel, F.R.1
  • 46
    • 33747825365 scopus 로고    scopus 로고
    • Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: Guarding against guessing
    • Lehtinen M., Apter D., Dubin G., et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS. 2006 ; 17: 517-521.
    • (2006) Int J STD AIDS , vol.17 , pp. 517-521
    • Lehtinen, M.1    Apter, D.2    Dubin, G.3
  • 47
    • 33645538848 scopus 로고    scopus 로고
    • Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy
    • Lehtinen M., Idanpaan-Heikkila I., Lunnas T., et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS. 2006 ; 17: 237-246.
    • (2006) Int J STD AIDS , vol.17 , pp. 237-246
    • Lehtinen, M.1    Idanpaan-Heikkila, I.2    Lunnas, T.3
  • 48
    • 20944448032 scopus 로고    scopus 로고
    • Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial
    • Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005 ; 6: 271-278.
    • (2005) Lancet Oncol , vol.6 , pp. 271-278
    • Villa, L.L.1    Costa, R.L.2    Petta, C.A.3
  • 49
    • 33845273878 scopus 로고    scopus 로고
    • High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
    • Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006 ; 95: 1459-1466.
    • (2006) Br J Cancer , vol.95 , pp. 1459-1466
    • Villa, L.L.1    Costa, R.L.2    Petta, C.A.3
  • 50
    • 34248326338 scopus 로고    scopus 로고
    • Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
    • The Future II Study Group
    • The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 ; 356: 1915-1927.
    • (2007) N Engl J Med , vol.356 , pp. 1915-1927
  • 51
    • 34249654115 scopus 로고    scopus 로고
    • Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials
    • Ault KA Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007 ; 369: 1861-1868.
    • (2007) Lancet , vol.369 , pp. 1861-1868
    • Ault, K.A.1
  • 52
    • 34248365967 scopus 로고    scopus 로고
    • Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    • Garland SM, Hernandez-Avila M., Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 ; 356: 1928-1943.
    • (2007) N Engl J Med , vol.356 , pp. 1928-1943
    • Garland, S.M.1    Hernandez-Avila, M.2    Wheeler, C.M.3
  • 53
    • 8444249386 scopus 로고    scopus 로고
    • Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial
    • Harper DM, Franco EL, Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004 ; 364: 1757-1765.
    • (2004) Lancet , vol.364 , pp. 1757-1765
    • Harper, D.M.1    El, F.2    Wheeler, C.3
  • 54
    • 33646058566 scopus 로고    scopus 로고
    • Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial
    • Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006 ; 367: 1247-1255.
    • (2006) Lancet , vol.367 , pp. 1247-1255
    • Harper, D.M.1    El, F.2    Wheeler, C.M.3
  • 55
    • 34250850161 scopus 로고    scopus 로고
    • Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial
    • Paavonen J., Jenkins D., Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007. In press.
    • (2007) Lancet
    • Paavonen, J.1    Jenkins, D.2    Bosch, F.X.3
  • 56
    • 33847391616 scopus 로고    scopus 로고
    • Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: A randomized controlled trial
    • Reisinger KS, Block SL, Lazcano-Ponce E., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007 ; 26: 201-209.
    • (2007) Pediatr Infect Dis J , vol.26 , pp. 201-209
    • Reisinger, K.S.1    Block, S.L.2    Lazcano-Ponce, E.3
  • 57
    • 33750938518 scopus 로고    scopus 로고
    • Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women
    • Block SL, Nolan T., Sattler C., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006 ; 118: 2135-2145.
    • (2006) Pediatrics , vol.118 , pp. 2135-2145
    • Block, S.L.1    Nolan, T.2    Sattler, C.3
  • 58
    • 34548453304 scopus 로고    scopus 로고
    • Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV 16/18 ASO4 candidate vaccine
    • Gall S., Teixeira J., Wheeler C., et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV 16/18 ASO4 candidate vaccine. American Association of Cancer Research Annual Meeting ; April 2007 ; Los Angeles, CA.
    • American Association of Cancer Research Annual Meeting
    • Gall, S.1    Teixeira, J.2    Wheeler, C.3
  • 59
    • 33646546302 scopus 로고    scopus 로고
    • Aging of the immune system: How much can the adaptive immune system adapt
    • Weng NP Aging of the immune system: how much can the adaptive immune system adapt ? Immunity. 2006 ; 24: 495-499.
    • (2006) Immunity , vol.24 , pp. 495-499
    • Weng, N.P.1
  • 60
    • 0033947903 scopus 로고    scopus 로고
    • Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis
    • Myers ER, McCrory DC, Nanda K., Bastian L., Matchar DB Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000 ; 151: 1158-1171.
    • (2000) Am J Epidemiol , vol.151 , pp. 1158-1171
    • Myers, E.R.1    McCrory, D.C.2    Nanda, K.3    Bastian, L.4    Matchar, D.B.5
  • 62
    • 27944491473 scopus 로고    scopus 로고
    • Pediatricians' intention to administer human papillomavirus vaccine: The role of practice characteristics, knowledge, and attitudes
    • Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005 ; 37: 502-510.
    • (2005) J Adolesc Health , vol.37 , pp. 502-510
    • Kahn, J.A.1    Zimet, G.D.2    Di, B.3
  • 63
    • 27944445968 scopus 로고    scopus 로고
    • Impact of HPV infection in adolescent populations
    • Moscicki AB Impact of HPV infection in adolescent populations. J Adolesc Health. 2005 ; 37: 3S - 9S.
    • (2005) J Adolesc Health , vol.37
    • Ab, M.1
  • 64
    • 48449106160 scopus 로고    scopus 로고
    • HPV type 6/11/16/18 vaccine: First analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18
    • Brown D. HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. Paper presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ; September 2007 ; Chicago, IL.
    • Paper Presented At: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Brown, D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.